trial

DECIFER: Depression and Citalopram In First Episode Recovery

NCTId NCT01041274
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 95 (actual)
Sponsored by NYU Langone Health
Primary completion 2014-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
95 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2010-01
Primary completion
2014-12
Eligibility
ALL · 16 Years · 40 Years

Interventions & indications

Drugs
CitalopramPsychoeducationCognitive Behavioral Therapy (CBT)Functional Magnetic Resonance Imaging (fMRI)

Sponsors

NYU Langone HealthLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Donald C. Goff, MDPrincipal Investigator

Sites

1 total
New York, United States

Facts & assertions

4 sourced
Enrollment
95
Phase
PHASE4
Primary Completion Date
2014-12
Status
COMPLETED
relationships
The graph out of here
drug
Citalopram
drug
Psychoeducation
drug
Cognitive Behavioral Therapy (CBT)
drug
Functional Magnetic Resonance Imaging (fMRI)
drug
lead_sponsor
NYU Langone Health
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophreniform Disorder
indication
Schizophrenia
indication
investigator
Donald C. Goff, MD
person